Chemoprevention of second cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2033-2037

  Mayne, Susan T ^a   Cartmel, Brenda ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CAROTENOID; ISOTRETINOIN; LETROZOLE; PLACEBO; RALOXIFENE; RETINOID DERIVATIVE; RETINOL PALMITATE; SELENIUM; TAMOXIFEN; TRASTUZUMAB; VITAMIN D;

ADENOMATOUS POLYP; ALCOHOL CONSUMPTION; BREAST CANCER; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; CLINICAL TRIAL; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; DIET SUPPLEMENTATION; DIET THERAPY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FERRET; HEAD AND NECK CANCER; HEREDITY; HUMAN; LIFESTYLE; LOW FAT DIET; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; SHORT SURVEY; SKIN CANCER; TOBACCO; VITAMIN BLOOD LEVEL;

ALCOHOL DRINKING; ANTICARCINOGENIC AGENTS; BETA CAROTENE; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; NUTRITIONAL STATUS; SMOKING;

EID: 33845293445     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0415     Document Type: Short Survey

References (38)

1. Travis LB. The epidemiology of second primary cancers [invited mini-review]. Cancer Epidemiol Biomarkers Prev 2006;15(11).
2. Travis LB, Rabkin C, Brown LM, et al. Cancer survivorship - genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.
3. Vogel V. Identifying and screening patients at risk of second cancers. Cancer Epidemiol Biomarkers Prev 2006;15(11).
4. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
5. Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention. Vol. 1. Promising cancer chemopreventive agents. Totowa (New Jersey): Humana Press; 2004. 697 pages.
6. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
7. The α-Tocopherol, β Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
8. Greenberg ER, Baron JA, Stukell TA, et al. A clinical trial of β carotene to prevent basal-cell and squamous-cell cancers of the skin. N Engl J Med 1990;323:789-95.
9. Albanes D, Heinonen OP, Taylor PR, et al. α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-Tocopherol, β-Carotene Cancer Prevention Study: effects of baseline characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70.
10. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of β carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
11. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with β carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
12. Mayne ST. β-Carotene, carotenoids and cancer prevention. 5th ed. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Principles and practice of oncology (PPO). Updates. Vol. 12. Philadelphia: Lippincott-Raven Publishers; 1998. p. 1-15.
13. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russell RM. Retinoid signaling and activator protein-1 expression in ferrets given β-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 1999;91:60-6.
14. Mayne ST, Lippman SL. Cigarettes: a smoking gun in cancer chemoprevention. J Natl Cancer Inst 2005;97:1319-21.
15. Mayne ST, Lippman SM. Cancer prevention: diet and chemopreventive agents. Retinoids, carotenoids, and other micronutrients. 7th ed. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 521-36.
16. Longnecker MP. Alcohol consumption and risk of cancer in humans: an overview. Alcohol 1995;12:87-96.
17. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994;331:141-7.
18. Baron JA, Cole BF, Mott L, et al. Neoplastic and antineoplastic effects of β-carotene on colorectal adenoma recurrence: results of a randomized trial. J Natl Cancer Inst 2003;95:717-22.
19. Lagakos SW. The challenge of subgroup analysis - reporting without distorting. N Engl J Med 2006;354:1667-9.
20. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6.
21. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:893-9.
22. Kirsh VA, Hayes RB, Mayne ST, et al.; on behalf of the PLCO Trial. Supplemental and dietary vitamin E, β-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006;98:245-54.
23. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
24. El-Bayoumy K. Not all chemopreventive selenium compounds are created equal. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention. Vol. 1. Promising cancer chemopreventive agents. Totowa (New Jersey): Humana Press; 2004. p. 537-45.
25. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957-63.
26. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9.
27. Reid MR, Duffield-Lillico AJ, Sunga A, et al. Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer 2006;118:1777-81.
28. Baron JA, Beach M, Mandel JS, et al.; Calcium Polyp Prevention Study Group. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999;340:101-7.
29. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003;95:1765-71.
30. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
31. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
32. Smith CL. Breast cancer chemoprevention by selective estrogen receptor modulators. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention. Vol. 1. Promising cancer chemopreventive agents. Totowa (New Jersey): Humana Press; 2004. p. 245-56.
33. Jonat W, Hilpert F, Maass N. The use of aromatase inhibitors in adjuvant therapy for early breast cancer. Cancer Chemother Pharmacol 2005;56 Suppl 1:32-8.
34. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
35. Averbuch SD, Khuri FR. The potential of EGFR-targeted agents in cancer prevention. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention. Vol. 1. Promising cancer chemopreventive agents. Totowa (New Jersey): Humana Press; 2004. p. 317-24.
36. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.; for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
37. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
38. Available from: www.cancer.gov/clinicaltrials/results/low-fat-diet0505, accessed 3/14/06.